Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Feb 19;58(6):1312–1320. doi: 10.2337/db08-1651

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2009 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 3. — Increased Bmi1 and decreased p16 levels are coincident with adaptive β-cell mass expansion on exendin-4 treatment in young mice. A: Analysis of β-cell mass of young and old mice after 7 days' constitutive injection of exendin-4. Values are representative of five slides spanning the whole pancreas of each mouse and three mice per group. B: Percentage of Ki67-positive β-cells of young and old mice after 7 days of PBS or exendin-4 treatment. Values are averaged from slides for each mouse and three mice in each group. **P < 0.05. C: Percentage of PCNA-positive β-cells of young and old mice after 7 days of PBS or exendin-4 treatment. Values are averaged from slides for each mouse and three mice in each group. ***P < 0.005 comparing PBS– vs. exendin-4–treated groups. D– K: Pancreatic sections from young (D, E, H, and I) and old (F, G, J, and K) mice treated with either exendin-4 or PBS were immunostained with antibodies to insulin (green) and p16 (red) (D, E, F, and G), or to insulin (green) and Bmi1 (red) (H, I, J, and K). Ex-4, exendin-4. (A high-quality digital representation of this figure is available in the online issue).